Cyclosporine A for the treatment of refractory nephrotic syndrome with renal dysfunction

Gao,Xiang; Ma,Yiyi; Sun,Lijun; Chen,Dongping; Mei,Changlin; Xu,Chenggang

doi:10.3892/etm.2013.1446

2014-February Volume 7 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

2014-February Volume 7 Issue 2

Full Size Image

Article

Cyclosporine A for the treatment of refractory nephrotic syndrome with renal dysfunction

Authors:
- Xiang Gao
- Yiyi Ma
- Lijun Sun
- Dongping Chen
- Changlin Mei
- Chenggang Xu
View Affiliations / Copyright

Affiliations: Department of Medicine, Kidney Institute of PLA, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China
Pages: 447-450
|
Published online on: December 12, 2013

https://doi.org/10.3892/etm.2013.1446
Expand metrics +

Abstract

Cyclosporine A (CsA) is an immunosuppressant agent and is utilized as a second‑line drug therapy for refractory nephrotic syndrome (RNS). In general, the use of CsA is strictly controlled in patients with an estimated glomerular filtration rate (eGFR) <30‑40 ml/min/1.73 m2, and little is known about the safety and efficacy of CsA treatment in patients with RNS complicated by renal dysfunction. In the present study, the clinical data of 10 patients with RNS and renal dysfunction, who received CsA treatment between 2000 and 2009 in the Kidney Institute of PLA, were reviewed retrospectively. Pathologically, these patients included six cases with minimal change, two cases of diffuse mesangial proliferation and two cases of focal segmental glomerulosclerosis. Six months subsequent to the initiation of the CsA treatment, six patients achieved complete remission, two patients achieved remarkable remission and two patients achieved partial remission. Renal function was improved in all patients as represented by the improvement in the eGFR (28.6±3.8 ml/min/1.73 m2 prior to treatment versus 99.3±21.9 ml/min/1.73 m2 6 months subsequent to treatment). Few adverse CsA‑related events were observed. These results suggest that renal dysfunction is not an absolute contraindication for CsA treatment in patients with RNS. The use of CsA is safe and efficacious and may, in certain cases, improve renal function in patients with RNS and renal impairment.

View Figures

View References

1	Troyanov S, Wall CA, Miller JA, Scholey JW and Cattran DC; Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 16:1061–1068. 2005. View Article : Google Scholar : PubMed/NCBI
2	Ehrich JH, Geerlings C, Zivicnjak M, Franke D, Geerlings H and Gellermann J: Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant. 22:2183–2193. 2007. View Article : Google Scholar : PubMed/NCBI
3	Miroux C, Morales O, Ghazal K, et al: In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. Transplantation. 94:123–131. 2012. View Article : Google Scholar : PubMed/NCBI
4	Kamar N, Allard J, Ader JL and Rostaing L: Cyclosporine-A-based immunosuppression and renal functional reserve in organ-transplant patients. Transplant Proc. 36(2 Suppl): 248S–250S. 2004. View Article : Google Scholar : PubMed/NCBI
5	Jang HR, Jung HW, Lee YJ, et al: Combination treatment with corticosteroid, cyclosporine A, and mycophenolate in refractory nephrotic syndrome. Clin Nephrol. 75:511–517. 2011. View Article : Google Scholar : PubMed/NCBI
6	Kranz B, Vester U, Büscher R, Wingen AM and Hoyer PF: Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years. Pediatr Nephrol. 23:581–586. 2008.PubMed/NCBI
7	Group KDIGO. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2:139–274. 2012.
8	Kornberg A, Küpper B, Hommann M and Scheele J: Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction. Int Immunopharmacol. 5:141–146. 2005. View Article : Google Scholar
9	Cantarovich M, Tzimas GN, Barkun J, Deschênes M, Alpert E and Tchervenkov J: Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation. 76:98–102. 2003. View Article : Google Scholar : PubMed/NCBI
10	Prytula A, Iijima K, Kamei K, et al: Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 25:461–468. 2010. View Article : Google Scholar : PubMed/NCBI
11	Tocci MJ and Sigal NH: Recent advances in the mechanism of action of cyclosporine and FK506. Curr Opin Nephrol Hypertens. 1:236–242. 1992. View Article : Google Scholar : PubMed/NCBI
12	Jenkins MK, Schwartz RH and Pardoll DM: Effects of cyclosporine A on T cell development and clonal deletion. Science. 241:1655–1658. 1988. View Article : Google Scholar : PubMed/NCBI
13	Singh A, Tejani C and Tejani A: One-center experience with cyclosporine in refractory nephrotic syndrome in children. Pediatr Nephrol. 13:26–32. 1999. View Article : Google Scholar : PubMed/NCBI
14	Hamasaki Y, Yoshikawa N, Nakazato H, et al; for Japanese Study Group of Renal Disease in Children. Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis. Pediatr Nephrol. 28:765–771. 2013.PubMed/NCBI
15	Shehata M, el Nahas M, Barkworth E, Cope GH and Raftery AT: Localization of PDGF-BB in the juxtaglomerular cells of cyclosporin-treated rats. Exp Nephrol. 3:173–179. 1995.PubMed/NCBI
16	Shihab FS, Andoh TF, Tanner AM, et al: Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy. Kidney Int. 49:1141–1151. 1996. View Article : Google Scholar : PubMed/NCBI
17	Feutren G and Mihatsch MJ: Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med. 326:1654–1660. 1992. View Article : Google Scholar : PubMed/NCBI
18	Meyrier A: Treatment of idiopathic nephrotic syndrome with cyclosporine A. J Nephrol. 10:14–24. 1997.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Cyclosporine A for the treatment of refractory nephrotic syndrome with renal dysfunction

This article is mentioned in:

Abstract

Related Articles